Details

Autor(en) / Beteiligte

• Wang, Changyi
• Xu, Guodong
• Wen, Qi
• Peng, Xiaolin
• Chen, Hongen
• Zhang, Jingwen
• Xu, Shan
• Zhang, Chunhui
• Zhang, Min
• Ma, Jianping
• Hui, Zhaohui
• Wu, Guifu
• Ma, Min

Titel

CBS promoter hypermethylation increases the risk of hypertension and stroke

Ist Teil von

• Clinics (São Paulo, Brazil), 2019-01, Vol.74, p.e630-e630, Article e630

Ort / Verlag

Brazil: Elsevier España, S.L.U

Erscheinungsjahr

2019

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2–ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients.